Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Myunghwan Jung, Hongmin Kim, Eunsol Choi, Min-Kyoung Shin & Sung Jae Shin. (2024) Enhancing vaccine effectiveness in the elderly to counter antibiotic resistance: The potential of adjuvants via pattern recognition receptors. Human Vaccines & Immunotherapeutics 20:1.
Read now
Read now
Zhen-Zi Wang, Yu-Hua Gao, Ping Wang, Lin Wei, Chang-Ping Xie, Zhen-Xing Yang, Jian Lan, Zhong-Liao Fang, Ying Zeng, Ling Yan, Xue-En Liu & Hui Zhuang. (2018) Comparison of immunogenicity between hepatitis B vaccines with different dosages and schedules among healthy young adults in China: A 2-year follow-up study. Human Vaccines & Immunotherapeutics 14:6, pages 1475-1482.
Read now
Read now
Caroline Van Den Ende, Cinzia Marano, Ayla Van Ahee, Eveline M. Bunge & Laurence De Moerlooze. (2017) The immunogenicity and safety of GSK’s recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience. Expert Review of Vaccines 16:8, pages 811-832.
Read now
Read now
Alicja E Grzegorzewska. (2014) Hepatitis B vaccination in chronic kidney disease patients: a call for novel vaccines. Expert Review of Vaccines 13:11, pages 1317-1326.
Read now
Read now
Nelson F Eng, Nitin Bhardwaj, Rebecca Mulligan & Francisco Diaz-Mitoma. (2013) The potential of 1018 ISS adjuvant in hepatitis B vaccines. Human Vaccines & Immunotherapeutics 9:8, pages 1661-1672.
Read now
Read now
Nikolai Petrovsky. (2008) Freeing vaccine adjuvants from dangerous immunological dogma. Expert Review of Vaccines 7:1, pages 7-10.
Read now
Read now
Jiri Beran. (2008) Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opinion on Biological Therapy 8:2, pages 235-247.
Read now
Read now
Michael Kundi. (2007) New hepatitis B vaccine formulated with an improved adjuvant system. Expert Review of Vaccines 6:2, pages 133-140.
Read now
Read now
L. Ivanova & V. Russev. (2005) Hepatitis B Virus Vaccine Response in Children 15–19 Years Old. Biotechnology & Biotechnological Equipment 19:sup1, pages 78-80.
Read now
Read now
Karrar Ali Mohammed Hasan Alsakini, Ebru Sanci, Aylin Buhur, Altuğ Yavasoglu, N. Ülkü Karabay Yavasoglu & Ayşe Nalbantsoy. Single and repeat-dose toxicity and local tolerance assessment of newly developed oil emulsion adjuvant formulations for veterinary purposes. Drug and Chemical Toxicology 0:0, pages 1-12.
Read now
Read now
Articles from other publishers (33)
Yang Li, Ziwei Chen, Xinyi Lu, Jiufeng Sun, Mengyu Guo, Huige Zhou, Ru Bai, Yuliang Zhao, Chunying Chen & Yaling Wang. (2023) STING and TLR9 agonists synergistically enhance the immunogenicity of SARS-CoV-2 subunit vaccine. Nano Research 16:12, pages 13322-13334.
Crossref
Crossref
Simon Doss-Gollin, Sanya Thomas, Byron Brook, Kimia Abedi, Célia Lebas, Floriane Auderset, Yamile Lugo-Rodriguez, Guzman Sanchez-Schmitz, David J. Dowling, Ofer Levy & Simon D. van Haren. (2023) Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen. npj Vaccines 8:1.
Crossref
Crossref
Javier Castrodeza-Sanz, Iván Sanz-Muñoz & Jose M. Eiros. (2023) Adjuvants for COVID-19 Vaccines. Vaccines 11:5, pages 902.
Crossref
Crossref
Bishal Misra, Krystal A. Hughes & Sharan Bobbala. 2023. Nanomedicines for the Prevention and Treatment of Infectious Diseases. Nanomedicines for the Prevention and Treatment of Infectious Diseases
297
330
.
Eric W. Hall, Prabhu Gounder, John Angles, Noele P. Nelson, Eli S. Rosenberg & Mark K. Weng. (2022) Evaluating the cost‐effectiveness of hepatitis B vaccination strategies in high‐impact settings for adults. Journal of Viral Hepatitis 29:12, pages 1115-1126.
Crossref
Crossref
Joanna L Turley & Ed C Lavelle. (2022) Resolving adjuvant mode of action to enhance vaccine efficacy. Current Opinion in Immunology 77, pages 102229.
Crossref
Crossref
Ge Zhu, Yong-Guang Yang & Tianmeng Sun. (2022) Engineering optimal vaccination strategies: effects of physical properties of the delivery system on functions. Biomaterials Science 10:6, pages 1408-1422.
Crossref
Crossref
Daniel Tusé, Maria Malm, Kirsi Tamminen, André Diessner, Frank Thieme, Franziska Jarczowski, Vesna Blazevic & Victor Klimyuk. (2022) Safety and immunogenicity studies in animal models support clinical development of a bivalent norovirus-like particle vaccine produced in plants. Vaccine 40:7, pages 977-987.
Crossref
Crossref
Özgür M. Koc, Philippe de Smedt, Cécile Kremer, Geert Robaeys, Pierre van Damme, Niel Hens, Jorge Almeida, Frank Falkenberg, Paul Savelkoul & Astrid Oude Lashof. (2021) Immunogenicity and safety of HBAI20 Hepatitis B vaccine in non‐responders: Double‐blinded, randomised, controlled phase 2 trial. Liver International 41:10, pages 2318-2327.
Crossref
Crossref
Timo Vesikari, Joanne M Langley, Nathan Segall, Brian J Ward, Curtis Cooper, Guillaume Poliquin, Bruce Smith, Soren Gantt, Janet E McElhaney, Marc Dionne, Pierre van Damme, Isabel Leroux-Roels, Geert Leroux-Roels, Nathalie Machluf, Johanna N Spaans, Bebi Yassin-Rajkumar, David E Anderson, Vlad Popovic, Francisco Diaz-Mitoma, Timo Vesikari, Joanne M Langley, Soren Gantt, Marc Dionne, Janet McElhaney, Bruce Rankin, Carl Griffin, Mark Turner, Judith Kirstein, Barbara E Rizzardi, Hayes Williams, Anitta Ahonen, Olli Henriksson, Benita Ukkonen, Marita Paassilta, Nathan Segall, Brian J Ward, Curtis Cooper, Guillaume Poliquin, Bruce Smith, Pierre Van Damme, Isabel Leroux-Roels, Geert Leroux-Roels, Nathalie Machluf, Johanna N Spaans, Bebi Yassin-Rajkumar, David E Anderson, Vlad Popovic & Francisco Diaz-Mitoma. (2021) Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial. The Lancet Infectious Diseases 21:9, pages 1271-1281.
Crossref
Crossref
Konlavat Siriwattananon, Suwimon Manopwisedjaroen, Balamurugan Shanmugaraj, Eakachai Prompetchara, Chutitorn Ketloy, Supranee Buranapraditkun, Kittipan Tharakhet, Papatsara Kaewpang, Kiat Ruxrungtham, Arunee Thitithanyanont & Waranyoo Phoolcharoen. (2021) Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations. Vaccines 9:7, pages 744.
Crossref
Crossref
David Machin, Peter M. Fayers & Bee Choo Tai. 2021. Randomised Clinical Trials. Randomised Clinical Trials
503
522
.
B. V. Karalnik, B. I. Alimbekova & L. T. Eralieva. (2020) Coronavirus Infection and BCG Vaccination: Facts and Possibilities. Epidemiology and Vaccinal Prevention 19:5, pages 18-24.
Crossref
Crossref
Steven G. Reed, Darrick Carter, Corey Casper, Malcolm S. Duthie & Christopher B. Fox. (2018) Correlates of GLA family adjuvants’ activities. Seminars in Immunology 39, pages 22-29.
Crossref
Crossref
M.A. Tomai & J.P. Vasilakos. 2017. Immunopotentiators in Modern Vaccines. Immunopotentiators in Modern Vaccines
149
162
.
Luisa Circelli, Annacarmen Petrizzo, Maria Tagliamonte, Regina Heidenreich, Maria Lina Tornesello, Franco M. Buonaguro & Luigi Buonaguro. (2016) Immunological effects of a novel RNA-based adjuvant in liver cancer patients. Cancer Immunology, Immunotherapy 66:1, pages 103-112.
Crossref
Crossref
Ding YuanQin YuanQianqian CuiChaoqi LiuZhiyong ZhouHaixia ZhaoYaoyan DunTing WangChangcheng Zhang. (2016) Vaccine adjuvant ginsenoside Rg1 enhances immune responses against hepatitis B surface antigen in mice. Canadian Journal of Physiology and Pharmacology 94:6, pages 676-681.
Crossref
Crossref
Zhen-Zi Wang, Ming-Qiang Li, Ping Wang, Zhen-Xing Yang, Lin Wei, Ying Zeng, Yan-Ping Li, Ling Yan, Xue-En Liu & Hui Zhuang. (2016) Comparative immunogenicity of hepatitis B vaccine with different dosages and schedules in healthy young adults in China. Vaccine 34:8, pages 1034-1039.
Crossref
Crossref
Alberta Pasquale, Scott Preiss, Fernanda Silva & Nathalie Garçon. (2015) Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines 3:2, pages 320-343.
Crossref
Crossref
John J. Treanor, Robert L. Atmar, Sharon E. Frey, Robert Gormley, Wilbur H. Chen, Jennifer Ferreira, Robert Goodwin, Astrid Borkowski, Ralf Clemens & Paul M. Mendelman. (2014) A Novel Intramuscular Bivalent Norovirus Virus-Like Particle Vaccine Candidate—Reactogenicity, Safety, and Immunogenicity in a Phase 1 Trial in Healthy Adults. The Journal of Infectious Diseases 210:11, pages 1763-1771.
Crossref
Crossref
David Gordon, Peter Kelley, Susanne Heinzel, Peter Cooper & Nikolai Petrovsky. (2014) Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: A randomized controlled Phase 1 study. Vaccine 32:48, pages 6469-6477.
Crossref
Crossref
Steven G Reed, Mark T Orr & Christopher B Fox. (2013) Key roles of adjuvants in modern vaccines. Nature Medicine 19:12, pages 1597-1608.
Crossref
Crossref
Fadi Saade, Yoshikazu Honda-Okubo, Samay Trec & Nikolai Petrovsky. (2013) A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine 31:15, pages 1999-2007.
Crossref
Crossref
S.M. Sivakumar, Mohammed M. Safhi, M. Kannadasan & N. Sukumaran. (2011) Vaccine adjuvants – Current status and prospects on controlled release adjuvancity. Saudi Pharmaceutical Journal 19:4, pages 197-206.
Crossref
Crossref
Folkert Steinhagen, Takeshi Kinjo, Christian Bode & Dennis M. Klinman. (2011) TLR-based immune adjuvants. Vaccine 29:17, pages 3341-3355.
Crossref
Crossref
Alicja Chybicka, Teresa Jackowska, Anna Dobrzańska, Maciej Godycki-Ćwirko, Witold Lukas, Jacek Mrukowicz, Tomasz Paszkowski, Ryszard Poręba, Marek Spaczyński, Andrzej Steciwko, Leszek Szenborn & Jacek Wysocki. (2010) Zalecenia grupy ekspertów dotyczące pierwotnej profilaktyki raka szyjki macicy u dziewcząt i młodych kobiet. Pediatria Polska 85:4, pages 360-370.
Crossref
Crossref
David Machin & Peter M Fayers. 2010. Randomized Clinical Trials. Randomized Clinical Trials
337
348
.
. (2009) Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years. The Lancet 374:9706, pages 1975-1985.
Crossref
Crossref
Gholam Ali Ghorbani, Seyed Moaied Alavian & Hamid Reza Ghadimi. (2008) Long Term Effects of One or Two Doses of Hepatitis B Vaccine in Adults After Five Years. Pakistan Journal of Biological Sciences 11:4, pages 660-663.
Crossref
Crossref
Marianne A. B. van der Sande, Pauline A. Waight, Maimuna Mendy, Syed Zaman, Steve Kaye, Omar Sam, Abi Kahn, David Jeffries, Aveika A. Akum, Andrew J. Hall, Ebrima Bah, Samuel J. McConkey, Pierre Hainaut & Hilton C. Whittle. (2007) Long-Term Protection against HBV Chronic Carriage of Gambian Adolescents Vaccinated in Infancy and Immune Response in HBV Booster Trial in Adolescence. PLoS ONE 2:8, pages e753.
Crossref
Crossref
M.A.B. van der Sande, M. Mendy, P. Waight, C. Doherty, S.J. McConkey, A.J. Hall & H.C. Whittle. (2007) Similar long-term vaccine efficacy of two versus three doses of HBV vaccine in early life. Vaccine 25:8, pages 1509-1512.
Crossref
Crossref
Robert Perrillo & Satheesh Nair. 2006. Zakim and Boyer's Hepatology. Zakim and Boyer's Hepatology
635
663
.
G. Boland, J. Beran, M. Lievens, J. Sasadeusz, P. Dentico, H. Nothdurft, J.N. Zuckerman, B. Genton, R. Steffen, L. Loutan, J. Van Hattum & M. Stoffel. (2004) Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 23:3, pages 316-320.
Crossref
Crossref